$1.48
3.90% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US12529R1077
Symbol
CCCC
Sector
Industry

C4 Therapeutics Inc Stock price

$1.48
+0.08 5.71% 1M
-2.57 63.46% 6M
-2.12 58.89% YTD
-4.14 73.67% 1Y
-5.19 77.81% 3Y
-17.52 92.21% 5Y
-17.52 92.21% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.06 3.90%
ISIN
US12529R1077
Symbol
CCCC
Sector
Industry

Key metrics

Market capitalization $105.09m
Enterprise Value $-45.63m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.57
EV/Sales (TTM) EV/Sales -1.15
P/S ratio (TTM) P/S ratio 2.64
P/B ratio (TTM) P/B ratio 0.54
Revenue growth (TTM) Revenue growth 98.56%
Revenue (TTM) Revenue $39.78m
EBIT (operating result TTM) EBIT $-116.56m
Free Cash Flow (TTM) Free Cash Flow $-80.50m
Cash position $215.09m
EPS (TTM) EPS $-1.47
P/E forward negative
P/S forward 4.63
EV/Sales forward negative
Short interest 9.74%
Show more

Is C4 Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

C4 Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a C4 Therapeutics Inc forecast:

4x Buy
50%
4x Hold
50%

Analyst Opinions

8 Analysts have issued a C4 Therapeutics Inc forecast:

Buy
50%
Hold
50%

Financial data from C4 Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
40 40
99% 99%
100%
- Direct Costs 7.88 7.88
2% 2%
20%
32 32
159% 159%
80%
- Selling and Administrative Expenses 25 25
2% 2%
64%
- Research and Development Expense 115 115
4% 4%
290%
-109 -109
13% 13%
-273%
- Depreciation and Amortization 7.88 7.88
2% 2%
20%
EBIT (Operating Income) EBIT -117 -117
12% 12%
-293%
Net Profit -103 -103
18% 18%
-260%

In millions USD.

Don't miss a Thing! We will send you all news about C4 Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

C4 Therapeutics Inc Stock News

Neutral
GlobeNewsWire
14 days ago
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One Patient With a Minimal Residual Disease Negative Complete Response ; 40% ORR Achieved at the 75 µ g Dose Level
Neutral
GlobeNewsWire
3 months ago
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026
Neutral
GlobeNewsWire
3 months ago
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences.
More C4 Therapeutics Inc News

Company Profile

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Hirsch
Employees 110
Founded 2015
Website www.c4therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today